Pulmicort Respule®(AstraZeneca) contains a budesonide suspension approved for use with jet nebulizers based on registration trials with the LC Plus jet nebulizer (PARI). Ultrasonic nebulizers are not recommended for administration. The Aeroneb Go (Aerogen, Inc.), is an electronic micropump nebulizer that incorporates a piezo vibrational element to pump aerosol through an aperture plate. We wanted to determine ability of this technology to nebulize a suspension.
Budesonide suspension (Pulmicort Respules®; 0.5 mg/2 mL) was aerosolized with three LC Plus and three Aeroneb Go nebulizers To determine inhaled mass, aerosol was collected on a filter placed between the nebulizer mouthpiece and breathing simulator (Hans Rudolph; adult breathing pattern). The Mass Median Aerodynamic Diameter (MMAD) of the aerosol was determined with cascade impaction (Anderson Mk II). The amount of drug deposited was determined by HPLC. Treatment time was measured to the end of aerosol generation (Aeroneb Go) or one minute past sputter (LC Plus). All experiments were performed in triplicate.
Performance data are shown in the tableDevicesInhaled Mass (μg)Inhaled Mass (%)MMAD (μm)GSDTime (min)Aeroneb Go115±1322±33.1+0.11.6±0.16±0Pari LC Plus91±1418±33.8±0.42.3±1.16±0below. Both nebulizers had similar treatment times and inhaled mass of budesonide. The inhaled mass (%) for the LC Plus matches that previously reported by Smaldone et al (J Aerosol Med,1998;11:113-125.).
We conclude that the Aeroneb Go was as efficient as the jet nebulizer in delivering aerosolized budesonide solution.
New aerosol technologies, such as the electronic micropump, may deliver suspensions as well as the most efficient compressor nebulizer systems.
J.B. Fink, Aerogen, Inc.